May 18, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves Immgolis as first golimumab biosimilar for ulcerative colitis, RA
The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis. Golimumab-sldi (Immgolis, Accord BioPharma) has been approved as a biosimilar to golimumab (Simponi, Johnson & Johnson) for adults with moderately to severely active ulcerative colitis. It is administered via subcutaneous injection in a single-dose prefilled syringe.
427 words~2 min read
